Table 3.
Demographic, clinical features, and laboratory data of all the participants.
| Variables | AMI Group (n = 14) | Control (n = 8) | p-Value |
|---|---|---|---|
| Demographic features | |||
| Age (years) | 60.714 ± 3.010 | 60.571 ± 4.099 | 0.553 |
| Male/Female | 12/2 | 6/2 | 0.531 |
| Cardiovascular risk factors | |||
| Hypertension | 6 (42.86%) | 4 (50%) | 0.746 |
| Dyslipidemia | 1 (7.14%) | 0 | NA |
| Diabetes mellitus | 5 (35.71%) | 1 (12.5%) | NA |
| Current smoking | 8 (57.14%) | 2 (25%) | 0.145 |
| Vital signs on admission | |||
| SBP (mmHg) | 121.50 (114.75–140.50) | 120.00 (110.00–140.00) | 0.868 |
| DBP (mmHg) | 75.000 (69.500–94.000) | 72.000 (70.000–78.000) | 0.868 |
| Heart rate (bpm) | 78.000 (73.500–87.000) | 80.000 (75.000–84.000) | 0.973 |
| Echocardiographic finding | |||
| LVEF (%) | 52.500 ± 1.738 | 63.286 ± 1.848 | 0.001 |
| Laboratory findings | |||
| hs-cTnT (ng/mL) | 9.930 (8.138–10.000) | 0.007 (0.004–0.0100) | 0.000 |
| CKMB (U/L) | 342.00 (210.25–457.25) | 13.00 (9.00–15.00) | 0.000 |
| NT-pro-BNP (pg/mL) | 682.10 (266.33–894.50) | 68.00 (41.70–98.10) | 0.002 |
| TC (mmol/L) | 5.024 ± 0.199 | 3.556 ± 0.215 | 0.001 |
| TG (mmol/L) | 1.740 (0.758–2.395) | 2.280 (1.880–3.790) | 0.082 |
| LDL-C (mmol/L) | 3.161 ± 0.155 | 1.451 ± 0.217 | 0.000 |
| HDL-C (mmol/L) | 1.060 (0.833–1.365) | 0.860 (0.780–0.970) | 0.188 |
| Medications | |||
| Aspirin | 11 (78.57%) | 0 | NA |
| Clopidogrel | 2 (14.29%) | 0 | NA |
| Ticagrelor | 9 (64.29%) | 0 | NA |
| Statin | 7 (50%) | 0 | NA |
| ACEI/ARB | 2 (14.29%) | 3 (37.5%) | 0.211 |
| ß blocker | 3 (21.43%) | 2 (25%) | 0.848 |
| CCB | 6 (42.86%) | 0 | NA |
SBP: systolic blood pressure; DBP: diastolic blood pressure; LVEF: left ventricular ejection fraction; hs-cTnT: high-sensitivity cardiac troponin T; CKMB: creatine kinase-MB; NT-pro-BNP: n-terminal pro-B-type natriuretic peptide; TC: total cholesterol; TG: triglyceride; LDL-C: low-density lipoprotein-cholesterol; HDL-C: high-density lipoprotein-cholesterol; ACEI: angiotensin converting enzyme inhibitors; ARB: angiotensin II receptor blockers; and CCB: calcium channel blockers.